While this is the largest study to date measuring apoE glycosylation in relation to AD biomarkers, the main limitation to this study is the lack of APOE Ɛ4 homozygotes in the MCI and AD groups that would allow us to make further inferences on the effect of CSF apoE glycosylation on cognitive status. The gene discussed is APOE; the disease is Alzheimer disease.